RxDoctor Payments Data

Christine Bui

Optometrist · Venice, FLNPI 1396313607

Payments from drug & device makers

$1,538in general payments, 2019–2025

Across 30 payments — averaging $51.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$421
  • Dompe US, Inc.$313
  • AbbVie$234
  • Coopervision Inc.$197
  • Glaukos Corporation$182
  • Alcon$99
  • plus $92 from 3 others

What the payments were for

  • Food & beverage$1,538100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,538 in reported general payments places this provider in the 60th percentile of 3,166 optometrist providers in Florida.

See all optometrist providers in Florida

Medicare billing

Part B allowed, 2024
$203,620
Medicare patients
1,320
Services billed
2,503

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine63$99,211
XiidraLifitegrast63$93,856
Cyclosporine25$15,254
LumiganBimatoprost12$4,368
Latanoprost185$2,124
Travoprost17$2,069
Timolol Maleate52$1,749
Tobramycin-DexamethasoneTobramycin/Dexamethasone42$1,524
Fluorometholone21$1,309
Prednisolone Acetate20$1,030
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha64$721
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat42$646
Cephalexin41$365
Dorzolamide Hcl14$274
Brimonidine Tartrate36$249

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$234$103,58075 claims
Bausch & Lomb Americas Inc.Xiidra$421$93,85663 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,166 optometrist providers in Florida.

Other optometrist in Venice

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →